Synonyms: compound 57 [PMID: 30199637] | LIT001
Compound class:
Synthetic organic
Comment: LIT-001 is a non-peptide oxytocin (OT) receptor agonist [1]. The compound is proposed as being brain penetrant and to be active in vivo by intraperitoneal injection in mice. OT receptor agonists are predicted to promote prosocial effects in neurological conditions such as autism spectrum disorders (ASD), where interaction deficits are prevalent. LIT-001 provides an in vivo pharmacological tool compound that is suitable for furthering the study of the effects of OT receptor agonism in autism. The primary reference for LIT-001 by Frantz et al. defines the molecule as the S isomer (and as the trifluoroacetate salt) [1]. We display the free base here.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Peripheral intraperitoneal administration of LIT-001 leads to a reduction in social interaction deficits in the Oprm1-/- mouse model of autism [1]. Activation of V2 receptors by LIT-001 is unlikely to impact social behaviour as V2 receptors are not expressed in the central nervous system, but it may contribute to fluid retention [2]. |
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|